According to the announcement by Pharming Group N.V., the company will take part in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, in New York. This event, which is by invitation only, brings together innovative companies and investors focused on rare diseases.
Keynote Speech
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Anurag Relan, M.D., Chief Medical Officer of Pharming, will participate in an informal discussion focused on the market for Hereditary Angioedema (HAE) at 1:50 PM Eastern Time (7:50 PM CET).
Scheduling Individual Meetings
To arrange a one-on-one meeting with the Pharming management team, interested parties are invited to contact the investor relations via the provided email address or through their Oppenheimer representative.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 162,7 millions de dollars
Quarterly revenue: 162,7 millions de dollars
Revenue growth: -6 %
EBITDA: 2,4 millions de dollars
Net income: -3,6 millions de dollars
Risks mentioned
Baisse de 12 % des revenus RUCONEST sur le semestre, tirée par les volumes
Perte opérationnelle de 3,6 M$ contre un profit de 3,8 M$ un an plus tôt
Dépréciations de stocks portées à 16,6 M$ au bilan au 30 juin 2026
Opportunities identified
Progression de 37 % des revenus Joenja au premier semestre 2026
Autorisation de mise sur le marché européenne de Joenja obtenue le 22 mai 2026
Amélioration de 15 M$ de la prévision de charges opérationnelles 2026
Outlook / guidance
Expected revenue: 375 millions de dollars
Management commentary: Total revenues between US$375.0 million and US$395.0 million (0% to 5% growth), updated to reflect a US$30 million reduction compared with prior guidance.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
